Tradestie Institutional Equity Comparison Engine
CTKB vs MXCT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CTKB Overall Edge
CTKB Captures Institutional Edge (3โ0 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cytek Biosciences, Inc. Common Stock (CTKB) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CTKB trades at N/M Forward P/E with -22.5% operating margin (+1.8% YoY revenue) versus MXCT at N/M Forward P/E and -85.5% operating margin (+48.7% YoY). In options structure, CTKB sits in CONSOLIDATION (<1st %ile IV; Dealer Gamma Walls on Pro) against MXCT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CTKB N/M vs MXCT N/M Fwd P/E
Growth & Margin Winner
CTKB
Op Margin -22.5% vs -85.5% ยท YoY +1.8% vs +48.7%
Momentum & Technical Winner
CTKB
1Y +16.4% vs -19.4% ยท 52W Pos 91% vs 63%
Options & Structure Winner
CTKB
CONSOLIDATION (<1st %ile IV) vs UNCLASSIFIED (N/A IV)
CTKB
NASDAQ
Cytek Biosciences, Inc. Common Stock
Laboratory Analytical Instruments
$6.12
-3.16% 1D
Market Cap
$826.6M
1M Return
+12.71%
1Y Return
+16.35%
Forward P/E
N/M
Unified AI Score
48.4 / 100
HOLD
Tech 33.0
Fund 44.0
Flow 60.0
Mom 41.1
MXCT
NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap
$132.2M
1M Return
-4.2%
1Y Return
-19.41%
Forward P/E
N/M
Unified AI Score
41.7 / 100
SELL
Tech 46.0
Fund 52.0
Flow 62.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CTKB +16.35%
MXCT -19.41%
Spread: +35.76 pp (CTKB Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CTKB Revenue | MXCT Revenue | CTKB Op. Margin | MXCT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | N/A | $10M | N/A | -93.7% | MXCT |
| FY2020 | $90M | $20M | 14.7% | -71.6% | CTKB |
| FY2021 | $130M | $20M | 7.2% | -84.3% | CTKB |
| FY2022 | $160M | $30M | -1.1% | -95.2% | CTKB |
| FY2023 | $190M | $20M | -14.4% | -247.7% | CTKB |
| FY2024 | $200M | $20M | -10.2% | -230.5% | CTKB |
| FY2025 | $200M | $20M | -20.0% | -247.6% | CTKB |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CTKB | MXCT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $826.6M | $132.2M | Larger Scale | CTKB |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +1.8% | +48.7% | Higher Growth | MXCT |
| Operating Margin (TTM) Profitability | -22.5% | -85.5% | Higher Margin | CTKB |
| Net Profit Margin Profitability | -39.1% | -81.4% | Higher Margin | CTKB |
| Return on Equity (ROE) Capital Efficiency | -23.2% | -16.9% | Higher ROE | MXCT |
| 52-Week Range Position Momentum | 91% ($3โ$6) | 63% ($1โ$2) | Stronger Trend | CTKB |
| Beta / 30D Volatility Risk Regime | 0.71ฮฒ ยท 67% Vol | 1.19ฮฒ ยท 96% Vol | Lower Realized Risk | CTKB |
| Unified Institutional Score Composite Signal | 48.4 / 100 (HOLD) | 41.7 / 100 (SELL) | Higher Composite | CTKB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CTKB vs MXCT Buy Guide
CTKB
CONSOLIDATION
16d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
MXCT
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CTKB nor MXCT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.